O	0	6	EFFECT
O	6	7	:
O	8	9	a
O	10	20	randomized
O	21	26	phase
O	27	29	II
O	30	35	study
O	36	38	of
O	39	47	efficacy
O	48	51	and
O	52	58	impact
O	59	61	on
O	62	70	function
O	71	73	of
O	74	77	two
O	78	83	doses
O	84	86	of
B-intervention	87	90	nab
I-intervention	90	91	-
I-intervention	91	101	paclitaxel
O	102	104	as
O	105	110	first
O	110	111	-
O	111	115	line
O	116	125	treatment
O	126	128	in
O	129	134	older
O	135	140	women
O	141	145	with
O	146	154	advanced
O	155	161	breast
O	162	168	cancer
O	168	169	.

O	170	177	Limited
O	178	182	data
O	183	186	are
O	187	196	available
O	197	206	regarding
O	207	210	the
O	211	214	use
O	215	217	of
O	218	221	nab
O	221	222	-
O	222	232	paclitaxel
O	233	235	in
O	236	241	older
O	242	250	patients
O	251	255	with
O	256	262	breast
O	263	269	cancer
O	269	270	.

O	271	272	A
O	273	279	weekly
O	280	288	schedule
O	289	291	is
O	292	303	recommended
O	303	304	,
O	305	308	but
O	309	314	there
O	315	317	is
O	318	319	a
O	320	327	paucity
O	328	330	of
O	331	339	evidence
O	340	349	regarding
O	350	353	the
O	354	361	optimal
O	362	366	dose
O	366	367	.

O	368	370	We
O	371	380	evaluated
O	381	384	the
O	385	393	efficacy
O	394	396	of
O	397	400	two
O	401	410	different
O	411	416	doses
O	417	419	of
O	420	426	weekly
O	427	430	nab
O	430	431	-
O	431	441	paclitaxel
O	441	442	,
O	443	447	with
O	448	449	a
O	450	458	specific
O	459	464	focus
O	465	467	on
O	468	473	their
O	474	487	corresponding
O	488	494	impact
O	495	497	on
O	498	505	patient
O	506	514	function
O	514	515	,
O	516	518	in
O	519	524	order
O	525	527	to
O	528	535	address
O	536	539	the
O	540	544	lack
O	545	547	of
O	548	552	data
O	553	565	specifically
O	566	574	relating
O	575	577	to
O	578	581	the
O	582	587	older
O	588	598	population
O	598	599	.

O	600	606	EFFECT
O	607	609	is
O	610	612	an
O	613	617	open
O	617	618	-
O	618	623	label
O	623	624	,
O	625	630	phase
O	631	633	II
O	634	639	trial
O	640	647	wherein
B-total-participants	648	651	160
B-eligibility	652	657	women
I-eligibility	658	662	with
I-eligibility	663	671	advanced
I-eligibility	672	678	breast
I-eligibility	679	685	cancer
O	686	690	aged
B-age	691	692	≥
I-age	693	695	65
I-age	696	701	years
O	702	706	were
O	707	715	enrolled
O	716	720	from
O	721	723	15
O	724	736	institutions
O	737	743	within
B-location	744	749	Italy
O	749	750	.

O	751	759	Patients
O	760	764	were
O	765	773	randomly
O	774	782	assigned
O	783	784	1
O	784	785	:
O	785	786	1
O	787	789	to
O	790	797	receive
O	798	801	nab
O	801	802	-
O	802	812	paclitaxel
O	813	816	100
O	817	819	mg
O	819	820	/
O	820	822	m2
O	823	824	(
O	824	827	arm
O	828	829	A
O	829	830	)
O	831	833	or
O	834	837	125
O	838	840	mg
O	840	841	/
O	841	843	m2
O	844	845	(
O	845	848	arm
O	849	850	B
O	850	851	)
O	852	854	on
O	855	859	days
O	860	861	1
O	861	862	,
O	863	864	8
O	864	865	,
O	866	869	and
O	870	872	15
O	873	875	on
O	876	877	a
O	878	880	28
O	880	881	-
O	881	884	day
O	885	890	cycle
O	890	891	,
O	892	894	as
O	895	900	first
O	900	901	-
O	901	905	line
O	906	915	treatment
O	916	919	for
O	920	928	advanced
O	929	936	disease
O	936	937	.

O	938	941	The
O	942	949	primary
O	950	958	endpoint
O	959	962	was
B-outcome-Measure	963	968	event
I-outcome-Measure	968	969	-
I-outcome-Measure	969	973	free
I-outcome-Measure	974	982	survival
I-outcome-Measure	983	984	(
I-outcome-Measure	984	987	EFS
I-outcome-Measure	987	988	)
O	988	989	,
O	990	997	wherein
O	998	1000	an
O	1001	1006	event
O	1007	1010	was
O	1011	1018	defined
O	1019	1021	as
O	1022	1029	disease
O	1030	1041	progression
O	1042	1043	(
O	1043	1045	PD
O	1045	1046	)
O	1046	1047	,
O	1048	1058	functional
O	1059	1066	decline
O	1067	1068	(
O	1068	1070	FD
O	1070	1071	)
O	1071	1072	,
O	1073	1075	or
O	1076	1081	death
O	1081	1082	.

O	1083	1085	In
O	1086	1090	each
O	1091	1094	arm
O	1094	1095	,
O	1096	1099	the
O	1100	1104	null
O	1105	1115	hypothesis
O	1116	1120	that
O	1121	1124	the
O	1125	1131	median
O	1132	1135	EFS
O	1136	1141	would
O	1142	1144	be
O	1145	1146	≤
O	1147	1148	7
O	1149	1155	months
O	1156	1159	was
O	1160	1166	tested
O	1167	1174	against
O	1175	1176	a
O	1177	1180	one
O	1180	1181	-
O	1181	1186	sided
O	1187	1198	alternative
O	1199	1208	according
O	1209	1211	to
O	1212	1215	the
O	1216	1226	Brookmeyer
O	1227	1234	Crowley
O	1235	1239	test
O	1239	1240	.

O	1241	1250	Secondary
O	1251	1260	endpoints
O	1261	1269	included
B-outcome-Measure	1270	1279	objective
I-outcome-Measure	1280	1288	response
I-outcome-Measure	1289	1293	rate
I-outcome-Measure	1294	1295	(
I-outcome-Measure	1295	1298	ORR
I-outcome-Measure	1298	1299	)
O	1299	1300	,
B-outcome-Measure	1301	1309	clinical
I-outcome-Measure	1310	1317	benefit
I-outcome-Measure	1318	1322	rate
I-outcome-Measure	1323	1324	(
I-outcome-Measure	1324	1327	CBR
I-outcome-Measure	1327	1328	)
O	1328	1329	,
B-outcome-Measure	1330	1341	progression
I-outcome-Measure	1341	1342	-
I-outcome-Measure	1342	1346	free
I-outcome-Measure	1347	1355	survival
I-outcome-Measure	1356	1357	(
I-outcome-Measure	1357	1360	PFS
I-outcome-Measure	1360	1361	)
O	1361	1362	,
B-outcome-Measure	1363	1370	overall
I-outcome-Measure	1371	1379	survival
I-outcome-Measure	1380	1381	(
I-outcome-Measure	1381	1383	OS
I-outcome-Measure	1383	1384	)
O	1384	1385	,
O	1386	1389	and
B-outcome-Measure	1390	1396	safety
O	1396	1397	.

O	1398	1403	After
O	1404	1405	a
O	1406	1412	median
O	1413	1419	follow
O	1419	1420	-
O	1420	1422	up
O	1423	1425	of
O	1426	1428	32
O	1428	1429	.
O	1429	1430	6
O	1431	1437	months
O	1437	1438	,
O	1439	1442	140
B-outcome	1443	1449	events
O	1450	1454	were
O	1455	1463	observed
O	1464	1466	in
B-total-participants	1467	1470	158
O	1471	1480	evaluable
O	1481	1489	patients
O	1489	1490	.

B-outcome	1491	1497	Median
I-outcome	1498	1501	EFS
O	1502	1505	was
B-iv-cont-median	1506	1507	8
I-iv-cont-median	1507	1508	.
I-iv-cont-median	1508	1509	2
I-iv-cont-median	1510	1516	months
O	1517	1518	(
O	1518	1520	90
O	1520	1521	%
O	1522	1524	CI
O	1524	1525	,
O	1526	1527	5
O	1527	1528	.
O	1528	1529	9
O	1529	1530	-
O	1530	1531	8
O	1531	1532	.
O	1532	1533	9
O	1533	1534	;
O	1535	1536	p
O	1537	1538	=
O	1539	1540	0
O	1540	1541	.
O	1541	1544	188
O	1544	1545	)
O	1546	1548	in
O	1549	1552	arm
O	1553	1554	A
O	1555	1557	vs
B-cv-cont-median	1558	1559	8
I-cv-cont-median	1559	1560	.
I-cv-cont-median	1560	1561	3
I-cv-cont-median	1562	1568	months
O	1569	1570	(
O	1570	1572	90
O	1572	1573	%
O	1574	1576	CI
O	1576	1577	,
O	1578	1579	6
O	1579	1580	.
O	1580	1581	2
O	1581	1582	-
O	1582	1583	9
O	1583	1584	.
O	1584	1585	7
O	1585	1586	,
O	1587	1588	p
O	1589	1590	=
O	1591	1592	0
O	1592	1593	.
O	1593	1596	078
O	1596	1597	)
O	1598	1600	in
O	1601	1604	arm
O	1605	1606	B
O	1606	1607	.

B-outcome	1608	1619	Progression
I-outcome	1619	1620	-
I-outcome	1620	1624	free
I-outcome	1625	1633	survival
O	1633	1634	,
B-outcome	1635	1642	overall
I-outcome	1643	1651	survival
O	1651	1652	,
O	1653	1656	and
B-outcome	1657	1665	response
I-outcome	1666	1671	rates
O	1672	1676	were
O	1677	1684	similar
O	1685	1687	in
O	1688	1692	both
O	1693	1699	groups
O	1699	1700	.

O	1701	1702	A
O	1703	1709	higher
B-outcome	1710	1720	percentage
I-outcome	1721	1723	of
I-outcome	1724	1728	dose
I-outcome	1729	1739	reductions
I-outcome	1740	1743	and
I-outcome	1744	1760	discontinuations
I-outcome	1761	1764	due
I-outcome	1765	1767	to
I-outcome	1768	1775	adverse
I-outcome	1776	1782	events
I-outcome	1783	1784	(
I-outcome	1784	1787	AEs
I-outcome	1787	1788	)
O	1789	1792	was
O	1793	1798	noted
O	1799	1801	in
O	1802	1805	arm
O	1806	1807	B
O	1807	1808	.

O	1809	1812	The
O	1813	1817	most
O	1818	1828	frequently
O	1829	1837	reported
O	1838	1841	non
O	1841	1842	-
O	1842	1856	haematological
O	1857	1860	AEs
O	1861	1865	were
B-outcome	1866	1873	fatigue
I-outcome	1874	1875	(
I-outcome	1875	1880	grade
I-outcome	1881	1882	[
I-outcome	1882	1883	G
I-outcome	1883	1884	]
I-outcome	1885	1886	2
I-outcome	1886	1887	-
I-outcome	1887	1888	3
I-outcome	1889	1897	toxicity
I-outcome	1898	1908	occurrence
O	1909	1911	in
O	1912	1915	arm
O	1916	1917	A
O	1918	1920	vs
O	1921	1922	B
O	1922	1923	,
B-iv-bin-percent	1924	1926	43
I-iv-bin-percent	1926	1927	%
O	1928	1931	and
B-cv-bin-percent	1932	1934	51
I-cv-bin-percent	1934	1935	%
O	1935	1936	,
O	1937	1949	respectively
O	1949	1950	)
O	1951	1954	and
B-outcome	1955	1965	peripheral
I-outcome	1966	1976	neuropathy
O	1977	1978	(
O	1978	1980	G2
O	1980	1981	-
O	1981	1982	3
O	1983	1986	arm
O	1987	1988	A
O	1989	1991	vs
O	1992	1993	B
O	1993	1994	,
B-iv-bin-percent	1995	1997	19
I-iv-bin-percent	1997	1998	%
O	1999	2002	and
B-cv-bin-percent	2003	2005	38
I-cv-bin-percent	2005	2006	%
O	2006	2007	,
O	2008	2020	respectively
O	2020	2021	)
O	2021	2022	.

O	2023	2026	Pre
O	2026	2027	-
O	2027	2036	specified
O	2037	2045	outcomes
O	2046	2050	were
O	2051	2058	similar
O	2059	2061	in
O	2062	2066	both
O	2067	2076	treatment
O	2077	2081	arms
O	2081	2082	.

O	2083	2090	However
O	2090	2091	,
O	2092	2095	100
O	2096	2098	mg
O	2098	2099	/
O	2099	2101	m2
O	2102	2105	was
O	2106	2119	significantly
O	2120	2126	better
O	2127	2136	tolerated
O	2137	2141	with
O	2142	2147	fewer
B-outcome	2148	2161	neurotoxicity
I-outcome	2161	2162	-
I-outcome	2162	2169	related
I-outcome	2170	2176	events
O	2176	2177	,
O	2178	2190	representing
O	2191	2192	a
O	2193	2197	more
O	2198	2206	feasible
O	2207	2211	dose
O	2212	2214	to
O	2215	2217	be
O	2218	2229	recommended
O	2230	2233	for
O	2234	2239	older
O	2240	2248	patients
O	2249	2253	with
O	2254	2262	advanced
O	2263	2270	disease
O	2270	2271	.

O	2272	2279	EudraCT
O	2279	2280	,
O	2281	2285	2012
O	2285	2286	-
O	2286	2292	002707
O	2292	2293	-
O	2293	2295	18
O	2296	2297	.

O	2298	2308	Registered
O	2309	2311	on
O	2312	2316	June
O	2317	2318	4
O	2318	2319	,
O	2320	2324	2012
O	2324	2325	.

O	2326	2329	NIH
O	2330	2344	ClinicalTrials
O	2344	2345	.
O	2345	2348	gov
O	2348	2349	,
O	2350	2361	NCT02783222
O	2362	2363	.

O	2364	2379	Retrospectively
O	2380	2390	registered
O	2391	2393	on
O	2394	2397	May
O	2398	2400	26
O	2400	2401	,
O	2402	2406	2016
O	2406	2407	.
